Clearbridge Health rides on China's biotech boom for cancer diagnostic spinoff

SINGAPORE (Aug 31): Investors and foreign biotech veterans are making their way to China as the government aims to build a healthcare empire.

Jeremy Yee, former CEO of Cordlife Group and now running his second healthcare company Clearbridge Health, hopes to tap into that optimism. He plans to spin off a cancer diagnostics associate company that is aiming to expand into China, and buy more testing laboratories in the region. Yee hopes these moves will help revive investor interest in Clearbridge.

The company was listed last December; its shares hit 63 cents on Feb 1, but have since fallen more than 62% to close at 24 cents on Aug 30 and 14% below its IPO price of 28 cents.

---

Related Stories

• Biolidics raising $1.5 million by issuing new shares to investor from China
• Listing amendment for life sciences IPOs part of bigger aspiration
• This medical breakthrough has its origins in Singapore

---